Physician profile
David J Cohen
NPI 1881768158
$38,392.92
in general payments reported to CMS, 2019-2025
21 companies · $267 in 2025
The $267 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,899 · 2020: $8,140 · 2021: $16K · 2022: $11K · 2023: $43.18 · 2024: $17.79 · 2025: $267.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $328.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $327.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $11,635.39 | 2020-2022 | |
| Leo Pharma As | $9,633.86 | 2022 | |
| Impulse Dynamics (USA) INC. | $8,500.00 | 2021 | |
| Intercept Pharmaceuticals, INC. | $2,600.00 | 2019 | |
| Novartis Pharmaceuticals Corporation | $2,320.00 | 2021 | |
| Veloxis Pharmaceuticals, INC. | $1,757.89 | 2019-2020 | |
| Abbott Laboratories | $1,500.00 | 2022 | |
| Edwards Lifesciences Corporation | $210.87 | 2025 | Sapien 3 Ultra Resilia |
| Cathworks, INC. | $61.14 | 2022 | |
| Pfizer INC. | $41.47 | 2019 | |
| Kerecis Limited | $33.30 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Travere Therapeutics, INC. | $23.00 | 2023 | |
| Galderma Laboratories, L.P. | $22.45 | 2025 | Nemluvio |
| Takeda Pharmaceuticals U.S.A., INC. | $20.18 | 2023 | Livtencity |
| Regeneron Healthcare Solutions, INC. | $17.79 | 2024 | Dupixent |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.58 | 2022 |
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Cohen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.